[Edaily Reporter Hyera Lee ] #ROKIT HEALTHCARE Inc., an AI-based organ regeneration platform, surged 16% early in the session, continuing its upward trend for the fourth consecutive day. According to MP Doctor on the 15th, as of 9:27 a.m. today, ROKIT HEALTHCARE Inc. is trading at 53,000 won, up 16.81% from the previous trading day. The stock price surge is driven by the start of human clinical trials for kidney regeneration surgery. ROKIT HEALTHCARE Inc. announced on the 13th that it had obtained final approval for the related surgery from the Institutional Review Board (IRB) for Advanced Regenerative Medicine at a leading tertiary hospital in South Korea. Having cleared all regulatory hurdles following approval of its research plan by the Ministry of Health and Welfare last May, the company reported that surgeries on 10 patients with chronic kidney disease will begin this month. ROKIT HEALTHCARE Inc. official stated, “The core technology applied in these surgeries has already been patented in the United States, Japan, and South Korea,” adding, “We plan to pursue rapid approval for this advanced regenerative therapy as soon as the clinical trial is completed.”
The fundraising strategies of Korean companies seeking to grow their U.S. subsidiaries—which are expected to drive future growth—in local capital markets have hit a snag. With SK hynix suspending the …
The home shopping industry is accelerating its efforts to secure proprietary and exclusive products. Amid declining TV viewership and fierce competition with e-commerce platforms, the industry is purs…
Apple’s first foldable smartphone, the “iPhone Duo,” has received mixed reactions since its launch. While it has garnered praise for its sophisticated design and smooth folding mechanism—and pre-order…
